GlassScriptPhysician profile
Jenna Matthews
NPI 1689210924
$3,946.15
in general payments reported to CMS, 2019-2025
30 companies · $1,636 in 2025
The $1,636 reported for 2025 was more than what 91% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $28.17 · 2023: $998 · 2024: $1,284 · 2025: $1,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,907 · Education: $10.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,907.34 |
| Education | $10.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $500.65 | 2023-2025 | Jynarque |
| Travere Therapeutics, INC. | $499.99 | 2023-2025 | |
| Amgen INC. | $381.38 | 2023-2025 | Krystexxa, Tavneos |
| Astrazeneca Pharmaceuticals LP | $346.79 | 2023-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $227.24 | 2023-2025 | |
| Opko Pharmaceuticals, LLC | $221.34 | 2023-2025 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.36 | 2023-2025 | Jardiance |
| Vifor Pharma, INC. | $164.57 | 2023 | Veltassa, Korsuva |
| Calliditas Therapeutics US INC. | $162.80 | 2023-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $154.74 | 2023-2025 | Benlysta, Jesduvroq |
| Novartis Pharmaceuticals Corporation | $128.13 | 2023-2025 | |
| Novo Nordisk INC | $102.66 | 2025 | Ozempic, Rybelsus |
| Vantive US Healthcare LLC | $101.32 | 2025 | Renal - Acute, Renal - Pd |
| Ani Pharmaceuticals, INC. | $93.10 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $89.27 | 2023-2024 | Acthar, Terlivaz |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $85.29 | 2024-2025 | Ibsrela |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $73.65 | 2024-2025 | Voyxact |
| Akebia Therapeutics INC | $72.22 | 2024-2025 | Vafseo, Auryxia |
| Fresenius USA Marketing, INC. | $66.83 | 2024-2025 | Velphoro |
| Daiichi Sankyo INC. | $62.97 | 2023 | Injectafer |
| Horizon Therapeutics Plc | $59.36 | 2023 | Krystexxa |
| Baxter Healthcare | $27.10 | 2024 | Renal - Pd |
| Recor Medical INC | $25.48 | 2025 | Paradise Ultrasound Renal Denervation System |
| Takeda Pharmaceuticals U.S.A., INC. | $22.56 | 2023 | Gattex |
| Pharmacosmos Therapeutics INC. | $22.51 | 2023 | Monoferric |
| Lemaitre Vascular, INC. | $21.06 | 2025 | Artegraft Vascular Graft |
| Scpharmaceuticals INC. | $20.22 | 2025 | |
| Sanofi-Aventis U.S. LLC | $16.97 | 2021 | |
| Athena Bioscience, LLC | $16.39 | 2024 | Nexiclon Xr |
| Depuy Synthes Sales INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Matthews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.